Amgen's Strategy Analysis
Editor-reviewed by Ahmad Zaidi based on analysis by TransforML's proprietary AI
CEO, TransforML Platforms Inc. | Former Partner, McKinsey & Company
Strategy overview for Amgen
Amgen Inc.’s strategy is to treat serious illnesses across large patient populations by combining human genetics and artificial intelligence to accelerate novel biologic drug discovery while simultaneously capturing market share through a robust biosimilars portfolio. The company’s main advantage is its dual-pillar business model supported by advanced, agile biomanufacturing capabilities, which allows it to generate reliable revenue from off-patent competitor drugs to fund its own high-risk innovative pipeline. Its current priorities include advancing its AI-driven clinical pipeline, notably the MariTide obesity and cardiovascular treatment, expanding its sustainable biomanufacturing footprint in the United States and Puerto Rico, and scaling new direct-to-patient distribution models to improve medication access.
The biggest strategic question is whether Amgen can successfully transition its revenue reliance from legacy products facing imminent patent cliffs to its newer pipeline assets while navigating intense pricing pressures and mandatory Medicare price setting under the Inflation Reduction Act.
Amgen’s Strategy Visualized
Key Competitors for Amgen
AbbVie Inc.
Strong market position in immunology (Skyrizi, Rinvoq) and aggressive defense of market share through contracting and rebate strategies.
Novartis AG
Robust cardiovascular and immunology portfolios (Leqvio, Cosentyx) with strong global commercialization capabilities.
Regeneron Pharmaceuticals / Sanofi
Formidable presence in cardiovascular and inflammation markets (Praluent, Dupixent) and aggressive patent litigation strategies.
Johnson & Johnson
Deep expertise in immunology and oncology (Tremfya, Darzalex) with massive scale and integrated healthcare delivery influence.
Insights from Amgen's strategy and competitive advantages
What Stands Out in Amgen strategy and competitive advantage
Amgen's strategy is uniquely distinguished by its highly successful dual-pillar business model, which synergistically combines pioneering novel biologics with a robust, rapidly growing biosimilars portfolio. Unlike competitors such as AbbVie, which are primarily focused on defending against biosimilar erosion of their blockbusters (e.g., Humira), Amgen proactively leverages its biologics manufacturing expertise to capture market share from competitors' off-patent drugs. This offensive biosimilars strategy, generating $3.0 billion in 2025 with 37% year-over-year growth, provides a substantial, reliable revenue stream that de-risks and funds its high-cost, innovative R&D pipeline. This is a stark contrast to a company like Vertex, which relies on a 'serial innovation' model within a single, highly-focused therapeutic area.
Furthermore, Amgen’s innovation engine is specifically differentiated by its deep integration of AI with one of the world's richest human genetic datasets. While competitors like Pfizer and Merck KGaA also emphasize AI, Amgen's narrative explicitly links it to genetic validation, aiming to significantly shorten development timelines and increase the probability of success, as exemplified by the advancement of its differentiated obesity candidate, MariTide.
This R&D approach is underpinned by a distinct investment in agile, next-generation biomanufacturing ($1.9B in new US facilities), focusing on flexible, multi-product capabilities rather than simply scaling capacity for a single blockbuster, a potential advantage over Eli Lilly's massive but more narrowly focused manufacturing expansion for its GLP-1 franchise.
What are the challenges facing Amgen to achieve their strategy and competitive advantage
Amgen's primary challenge is the immense competitive pressure in the high-stakes obesity market, where it is a late entrant against deeply entrenched and rapidly scaling giants like Eli Lilly and Company. While Amgen's MariTide aims for differentiation through less frequent dosing, it must demonstrate overwhelming clinical and convenience superiority to capture significant share from Eli Lilly's Mounjaro and Zepbound, which are already experiencing meteoric growth (Lilly's revenue grew 32%).
A second major challenge is navigating the intense and direct impact of government pricing regulations, particularly the U.S. Inflation Reduction Act (IRA). Amgen has two of its own blockbuster drugs, ENBREL and Otezla, explicitly selected for mandatory Medicare price setting, creating a significant and predictable revenue headwind that is more immediate and specified than for some competitors. This is compounded by the cyclical pressure of its own patent cliffs, with Prolia and XGEVA facing biosimilar competition in 2025. This creates a high-stakes race where Amgen's pipeline, including MariTide, must execute flawlessly and commercialize rapidly to outpace the dual erosion from both IRA price cuts and biosimilar competition against its legacy products. While all major pharma companies face these pressures, the direct naming of Amgen's products for IRA negotiations makes this challenge particularly acute and central to its near-term strategy.
What Positions Amgen to win against competitors
Advanced Biomanufacturing Capabilities
- Industry-leading expertise in biologics manufacturing, supported by investments in next-generation, agile, and sustainable facilities in North Carolina, Ohio, and Puerto Rico that utilize AI-driven systems and robotics.
Robust Biosimilars Portfolio
- A highly successful biosimilars business that generated $3.0 billion in 2025 (growing 37% YoY), leveraging Amgen's technical expertise to succeed where others struggle and providing a strong secondary revenue stream.
AI and Human Genetics Integration
- Strong R&D foundation built on rich human genetic datasets and the integration of artificial intelligence to predict drug performance, generate novel proteins, and shorten the decade-long biologic development timeline.
Diversified Commercial Portfolio
- A broad portfolio across General Medicine, Rare Disease, Inflammation, and Oncology, with 18 products delivering record sales in 2025 and 14 exceeding $1.0 billion in annual sales.
Strong Financial Performance and Cash Generation
- Generated $36.8 billion in total revenues and $8.1 billion in free cash flow in 2025, enabling sustained R&D investments ($7.3 billion) and consistent shareholder returns (14 consecutive years of dividend growth).
Strategic Global Partnerships
- Effective collaborations with key global players, such as AstraZeneca for TEZSPIRE and BeOne Medicines for oncology expansion in China, which enhance global reach and share development costs.
What's the winning aspiration for Amgen strategy
Winning for Amgen means serving patients globally by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives, while delivering reliable supply, expanding access, and generating attractive long-term growth for shareholders.
Company Vision Statement:
To harness the best of biology and technology to fight the world's toughest diseases.
Where Amgen Plays Strategically
Amgen competes globally in the biopharmaceutical industry, focusing on serious illnesses with high unmet medical needs across four core therapeutic areas, while also competing aggressively in the biosimilars market.
Key Strategic Areas:
How Amgen tries to Win Strategically
Amgen wins by combining deep expertise in human genetics and novel biology with cutting-edge AI technology, executing with discipline in clinical development, and leveraging world-class, agile biomanufacturing capabilities.
Key Competitive Advantages:
Strategy Cascade for Amgen
Below is a strategy cascade for Amgen's strategy that has been formed through an outside-in analysis of publicly available data. Scroll down below the graphic to click on the arrows to expand each strategic pillar and see more details:
Related industry articles:
Advance Innovative Pipeline and AI-Driven R&D
Invest heavily in human genetics and artificial intelligence to accelerate drug discovery, predict drug performance, and advance a robust pipeline of novel biologics.
Advance MariTide Clinical Development
Initiate and execute multiple global Phase 3 clinical trials for MariTide targeting chronic weight management, cardiovascular disease, heart failure, and obstructive sleep apnea.
Integrate AI into Drug Discovery
Embed AI and machine learning platforms across the pipeline to identify genetically validated targets, generate novel proteins, and shorten the traditional decade-long biologic development timeline.
Build Thousand Oaks Innovation Center
Invest $600 million to build a new center for science and innovation capabilities at the Thousand Oaks, California headquarters to foster cross-functional R&D collaboration.
Expand and Modernize Global Biomanufacturing
Enhance global supply resilience and operational agility by investing in state-of-the-art, sustainable biomanufacturing facilities across the United States and Puerto Rico.
Expand North Carolina Facility
Complete the $1.0 billion expansion of the North Carolina drug substance manufacturing facility utilizing portable, flexible equipment to rapidly pivot between different medicines.
Scale Ohio Assembly and Packaging
Execute a $900 million investment in the New Albany, Ohio facility to support advanced final product assembly and packaging using state-of-the-art automation and robotics.
Implement Sustainable Operations
Implement sustainability measures across the manufacturing network to achieve ENERGY STAR certifications, reduce carbon footprint, and lower water consumption and waste.
Scale General Medicine for Large Patient Populations
Address large-scale health challenges such as cardiovascular disease, osteoporosis, and obesity with innovative therapies designed to reach massive patient populations globally.
Expand Repatha Market Reach
Capitalize on the broadened FDA approval for Repatha to reach adults at increased risk for major adverse cardiovascular events without requiring a prior cardiovascular disease diagnosis.
Accelerate EVENITY Adoption
Drive volume growth for EVENITY by targeting the estimated 2 million undiagnosed and untreated high-risk osteoporotic patients in the United States.
Execute Olpasiran Phase 3 Trials
Advance the large Phase 3 cardiovascular outcomes study for Olpasiran to rigorously test whether lowering elevated lipoprotein(a) can reduce major cardiovascular events.
Drive Growth in Biosimilars Portfolio
Leverage decades of biologics manufacturing expertise to develop and commercialize high-quality biosimilars, capturing market share from off-patent competitor drugs.
Launch Next-Generation Biosimilars
Launch and scale new biosimilars, including PAVBLU, WEZLANA, and BKEMV, to capture market share and generate returns in technically complex therapeutic areas.
Leverage Manufacturing for Biosimilars
Utilize existing global manufacturing scale and regulatory experience to efficiently navigate the abbreviated approval pathways for biosimilars in the U.S. and Europe.
Enhance Patient Access and Affordability
Address financial barriers to prescription medicines through innovative distribution models and strategic pricing approaches to ensure patients can affordably access therapies.
Scale AmgenNow Direct-to-Patient Program
Expand the AmgenNow direct-to-patient program to include additional medicines like Aimovig and AMJEVITA, reducing out-of-pocket costs and bypassing traditional pharmacy barriers.
Adapt to U.S. Pricing Regulations
Navigate U.S. pricing policies by taking actions that satisfy the Administration's Most-Favored-Nations (MFN) pricing requests and adapting to IRA Medicare price setting.
Read more about industry strategies
Source and Disclaimer: This analysis is based on analysis of Annual reports and other publicly available information. For informational purposes only (not investment, legal, or professional advice). Provided 'as is' without warranties. Trademarks and company names belong to their respective owners.